Zevra Therapeutics Inc ( ZVRA ) shares are trading higher by 3.1% to $8.11 Wednesday morning after the company reported better-than-expected first-quarter financial results.

What To Know: The rare disease-focused biotech posted a net loss of 6 cents per share, beating analyst estimates of a 20 cent loss and marking a sharp improvement from last year's 40 cent loss per share. Revenue soared to $20.4 million—up nearly 500% year-over-year—driven primarily by sales of MIPLYFFA and reimbursements for arimoclomol.

Read Also: Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

CEO Neil F. McFarlane emphasized the company's transformation into a commercial-stage, patient-centric therapeutics firm, with a strategic focus on expanding market access for MIPLYFFA and OLPRUVA.

Zevra says the company also continues to advance its pipeline, enrolling more patients in the Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome and planning to file a European marketing application for MIPLYFFA in the second half of 2025.

Zevra highlighted that the company’s financial position is bolstered by $150 million in gross proceeds from the recent sale of a Priority Review Voucher, bringing its post-quarter-end cash position to $217 million.

Read Also: Red Cat Holdings Stock Is Ripping Higher Wednesday: What’s Going On?

How To Buy ZVRA Stock

By now you're likely curious about how to participate in the market for Zevra Therapeutics ( ZVRA ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Zevra Therapeutics ( ZVRA ), which is trading at $8.47 as of publishing time, $100 would buy you 11.81 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, ZVRA has a 52-week high of $9.76 and a 52-week low of $4.20.